Table. Demographic and Clinical Characteristics for 126 Patients With Full Antibody Profilesa.
| Characteristic | Patients, No./total No. (%) | P value | |||
|---|---|---|---|---|---|
| Total (N = 126) | Children (n = 24) | Adolescents (n = 58) | Young adults (n = 44) | ||
| Positive RT-PCR testb | 9/47 (19.1) | 1/12 (8.3) | 3/29 (10.3) | 5/6 (83.3) | <.001 |
| RT-PCR test unavailable | 79/126 (62.7) | 12/24 (50) | 29/58 (50) | 38/44 (86.4) | <.001 |
| Race | |||||
| Asian | 7/124 (5.6) | 1/24 (4.2) | 4/58 (7.0) | 2/43 (4.7) | .04c |
| Black | 6/124 (4.8) | 1/24 (4.2) | 1/58 (1.8) | 4/43 (9.3) | |
| White | 55/124 (44.4) | 9/24 (37.5) | 31/58 (54.4) | 15/43 (34.9) | |
| Declined | 36/124 (29.0) | 7/24 (29.2) | 10/58 (17.5) | 19/43 (44.2) | |
| Otherd | 20/124 (16.1) | 6/24 (25.0) | 11/58 (19.3) | 3/43 (7.0) | |
| Sex | |||||
| Female | 64/126 (50.8) | 11/24 (45.8) | 28/58 (48.3) | 25/44 (56.8) | .60 |
| Male | 62/126 (49.2) | 13/24 (54.2) | 30/58 (51.7) | 19/44 (43.2) | |
| Age, y | |||||
| Median (range) | 16.0 (1.0-24.0) | 6.5 (1.0-10.0) | 15.0 (11.0- 18.0) | 21.0 (19.0-24.0) | NA |
| Mean (SD) | 15.4 (5.9) | 6.1 (3.2) | 14.6 (2.5) | 21.4 (1.6) | NA |
| Comorbidities | |||||
| Type 2 diabetes | 2/117 (1.7) | 0/21 | 1/52 (1.9) | 1/44 (2.3) | >.99 |
| Hypertension | 1/117 (0.9) | 0/21 | 0/52 | 1/44 (2.3) | .55 |
| Hyperlipidemia | 2/117 (1.7) | 0/21 | 0/52 | 2/44 (4.5) | .31 |
| Allergies | 18/117 (15.4) | 0/21 | 10/52 (19.2) | 8/44 (18.2) | .08 |
| Asthma | 12/117 (10.3) | 0/21 | 5/52 (9.6) | 7/44 (15.9) | .14 |
| Chronic lung disease | 1/117 (0.9) | 0/21 | 1/52 (1.9) | 0/44 | >.99 |
| Chronic cardiac disease | 5/117 (4.3) | 2/21 (9.5) | 1/52 (1.9) | 2/44 (4.5) | .26 |
| Current immunosuppression | 5/117 (4.3) | 1/21 (4.8) | 1/52 (1.9) | 3/44 (6.8) | .49 |
| COVID-19 exposure | 65/117 (55.6) | 18/21 (85.7) | 29/53 (54.7) | 18/43 (41.9) | .003 |
| Prior COVID-19 symptoms | |||||
| Previously symptomatic | 56/118 (47.5) | 10/21 (47.6) | 23/53 (43.4) | 23/44 (52.3) | .69 |
| Fever | 25/117 (21.4) | 7/21 (33.3) | 7/52 (13.5) | 11/44 (25) | .13 |
| Dyspnea | 2/117 (1.7) | 0/21 | 1/52 (1.9) | 1/44 (2.3) | >.99 |
| Cough | 22/117 (18.8) | 2/21 (9.5) | 10/52 (19.2) | 10/44 (22.7) | .50 |
| Anosmia or ageusia | 14/117 (12) | 0/21 | 7/52 (13.5) | 7/44 (15.9) | .16 |
| Sore throat | 6/117 (5.1) | 0/21 | 1/52 (1.9) | 5/44 (11.4) | .09 |
| Rhinorrhea | 10/117 (8.5) | 0/21 | 7/52 (13.5) | 3/44 (6.8) | .19 |
| Myalgia | 7/117 (6.0) | 0/21 | 1/52 (1.9) | 6/44 (13.6) | .05 |
| Fatigue | 13/117 (11.1) | 0/21 | 2/52 (3.8) | 11/44 (25) | .001 |
| Diarrhea | 4/117 (3.4) | 0/21 | 2/52 (3.8) | 2/44 (4.5) | >.99 |
| Emesis | 2/117 (1.7) | 0/21 | 0/52 | 2/44 (4.5) | .31 |
| Abdominal pain | 3/117 (2.6) | 1/21 (4.8) | 2/52 (3.8) | 0/44 | .40 |
| Headache | 10/117 (8.5) | 0/21 | 4/52 (7.7) | 6/44 (13.6) | .21 |
Abbreviations: COVID-19, coronavirus disease 2019; NA, not applicable; RT-PCR, reverse transcription–polymerase chain reaction.
a
Analyses used nonmissing values in both variables in the 2-way table. P values obtained from the statistical tests were by Fisher exact test.
b
RT-PCR testing performed prior to serological testing.
c
Fisher exact test (excluding other, declined, and unknown groups).
d
The other category included American Indian, Hispanic, Native Hawaiian, and others.